2022 ´ëÇÑ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-28±³À°ÀÏÀÚ : 2022-05-28
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ :
2022 ´ëÇÑ¿Ü°úÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) ÁÖÃÖ±â°ü : ´ëÇÑ¿Ü°úÇÐȸ
´ã´çÀÚ : ÇÏÁö¹Î
¿¬¶ôó : 02-797-1220
À̸ÞÀÏ :
wlals1935@gmail.com ±³À°Á¾·ù : ¿Ü°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 39 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í Àü¹®ÀÇ 110,000ºñȸ¿ø 140,000Àü°øÀÇ 80,000°øº¸ÀÇ / ±ºÀÇ°ü 80,000°£È£»ç/ ¿µ¾ç»ç / ¾à»ç 30,000Çлý / ÀÚ¹®À§¿ø / 65¼¼ÀÌ»ó ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 08:00~08:20 Àü°øÀÇ ¿¬Â÷º° ¼ö·Ã±³À° ³»¿ë ±èÀçÈÆ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 08:20~08:35 Àü°øÀÇ ÀÚÀ²Æò°¡ ¹ÚÁß¹Î(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 08:35~08:50 Àü°øÀÇ ¼ú±â¿¬¼ö±³À° ±è¼º±Ù(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 08:50~09:10 ´ëÇÑ¿Ü°úÇÐȸ E-learning ³²¼ÒÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 09:10~09:30 Àü°øÀÇ ¼ö·Ã±ÔÁ¤ÀÇ Àû¿ë ÀÌÀç¸í(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 08:00~08:25 ÃÑ·Ð I Wound Healing in Surgical Patients Á¶¿ë¼®(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 08:25~08:50 ÃÑ·Ð II Transfusion Principles in Surgical Patients °º´Èñ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 08:50~09:15 À§Àå°ü I Gastroesophageal Reflux Disease (GERD) Ä¡·áÀÇ ³»¿Ü°úÀû ÃÖ½ÅÁö°ß ¼Õ»ó¿ë(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 09:15~09:40 À§Àå°ü II À§Á¡¸·ÇÏÁ¾¾çÀÇ ºÐ·ù ¹× Ä¡·á ¹Ú±â¹ü(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 08:30~08:45 ÀÔ¹ý ¹è°æ°ú ±Ùº»ÀûÀÎ ´ë¾È ¹ÚÇü¿í(´ëÇÑÀÇÇÐȸ ¹ýÁ¦ÀÌ»ç)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 08:45~09:00 »çȸ¿¡¼ ¹Ù¶óº¸´Â ±èöÁß(ÀÇÇÐÀü¹®±âÀÚ)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 09:00~09:15 ¼ö·Ãº´¿ø¿¡¼ÀÇ ¹®Á¦Á¡°ú ´ë¾È ±èÁø(´ëÇÑ¿Ü°úÇÐȸ ¼ö·ÃÀÌ»ç)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 09:15~09:30 ¹ý¾È ÀÌÈÄ ¿¹»óµÇ´Â ¼ö¼ú½ÇÀÇ º¯ÈµÈ ¸ð½À°ú ½Ã¹ü»ç¾÷ÀÇ °æÇè Á¤ÀÏ¿ë(°æ±âµµ ÀÇ·á¿øÀå)
Åä·Ð 05-28 ´Ù¸ñÀû 1Ȧ 09:30~10:00 ÆгΠÅäÀÇ ()
±³À°½Ã°£ 05-28 201-203È£ 08:30~08:50 µð½ÃÁ¨-À¯¹æ¾Ï ´ÙÀ¯ÀüÀÚ ºÐ¼® Å°Æ® °³¹ß ÇÑ¿ø½Ä(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 08:50~09:10 3D Printing, Artificial Intelligence (AI), Virtual Reality (VR) À» ÀÌ¿ëÇÑ ¼ö¼ú ¹× Ä¡·áÀÇ Á¤¹Ð ¸ÂÃã ÀÇ·á ±¸Çö °í¹ü¼®(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 09:10~09:30 Equipments for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) TBD()
±³À°½Ã°£ 05-28 201-203È£ 09:30~09:50 ÀÇ»ç â¾÷ ¿¬±¸È¸ ¼Ò°³ È«À¯¼º(º¸°Ç»ê¾÷ÁøÈï¿ø)
Åä·Ð 05-28 201-203È£ 09:50~10:00 ÅäÀÇ ()
±³À°½Ã°£ 05-28 206-207È£ 08:30~10:00 Àü°øÀÇ ±¸¿¬ 2 TBD(TBD)
±³À°½Ã°£ 05-28 208-210È£ 09:40~10:00 °¿¬ 1: ½½±â·Î¿î ¿Ü°ú »ýÈ° ÀÌÃÊÀº(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 05-28 208-210È£ 10:00~10:20 °¿¬ 2: ´ëÇѹα¹ ¿Ü°úÀÇ ¹ßÀü Çü¿ìÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-28 214È£ 08:30~10:00 Àü°øÀÇ ±¸¿¬ 3 TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 10:00~10:40 ÀÇ»ç¿Í ÀÇ·áÀ±¸® ¾È¹®»ó(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 10:40~11:20 ÀÇ·á°¨¿° ±èÇüÁø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 11:20~12:00 ÀÇ·áºÐÀï¿¡ ´ëÇÑ Áö½Ä°ú ´ëÀÀ ±è¿¬Èñ(¹ý¹«¹ýÀÎ ÀǼº)
±³À°½Ã°£ 05-28 301-303È£ 10:00~10:25 °©»ó¼±³»ºÐºñ I Management of Hypoparathyroidism after Thyroid Surgery ¿øÅ¿Ï(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 10:25~10:50 °©»ó¼±³»ºÐºñ II °©»ó¼±¾Ï ¼ö¼úÀÇ ¿ª»ç¿Í ÇöÀç ±èÀ¯¼®(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 10:50~11:15 Ç÷°üÀÌ½Ä I Pharmacomechanical Thrombectomy with Angiojet for Acute Obstructive Lesions ÀÌÀçÈÆ(´ë±¸°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 11:15~11:40 Ç÷°üÀÌ½Ä II Recent Advances in Endovascular Treatment of Peripheral Arterial Disease ¹ÚÀÇÁØ(°è¸íÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 11:40~12:05 º¸Çè I ¿ì¸®³ª¶ó ÀǷẸÇèÁ¦µµ¿Í Diagnosis Related Group (DRG) ÀÇ ÀÌÇØ ±èÅÂÇü(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 10:30~10:50 ¸ÞŸ¹ö½º, Digital Twin + eXtended Reality (DT+XR) ±â¼úÀÇ ¿ªÇÒ°ú Àü¸Á ¿ì¿îÅÃ(KAIST ¹®È±â¼ú´ëÇпø)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 10:50~11:10 È®ÀåÇö½Ç(eXtended Reality, XR) ±â¹Ý ¿Ü°ú ±³À° (Surgical Training) ±èÀÏ(¼ÁöÄø¶Àεå)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 11:10~11:30 ¹Ìµð¾î/ÄÜÅÙÃ÷ »ê¾÷ ºÐ¾ß¿¡¼ÀÇ ¸ÞŸ¹ö½º ±èµ¿¾ð(VA Corporation)
Åä·Ð 05-28 ´Ù¸ñÀû 1Ȧ 11:30~11:50 ÆгΠÅäÀÇ °ø¼ºÈ£ / ¹ÚÁؼ®(¼¿ïÀÇ´ë / °æºÏÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 10:30~11:00 ¿©ÀÚ Àü°øÀÇÀÇ ¼ö·Ã ±ÔÁ¤ ±èÁø(´ëÇÑ¿Ü°úÇÐȸ ¼ö·ÃÀÌ»ç)
±³À°½Ã°£ 05-28 201-203È£ 11:00~11:20 ¿¬±¸ºñ ¹ßÇ¥ : ´ëÇÑ¿Ü°ú¿©ÀÚÀÇ»çȸ Çѱ¹ ¿©¼º ¿Ü°úÀÇ»çÀÇ ±Ù¹« ½ÇÅ ¹× À§»ó ¼³¹®Á¶»ç ÀÌÁÖ¿¬(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 11:20~12:00 Working with Women Surgeon ÀÌÀº¼÷(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 05-28 201-203È£ 11:20~12:00 ÆгΠÅäÀÇ °¼±Èñ / ±è½Â±â / ±è¿ëÈ£ / À°Á¤È¯ / ÃÖÁ¤Àº(°è¸íÀÇ´ë / Â÷ÀÇ´ë / °æÈñÀÇ´ë / ¿ï»êÀÇ´ë / ¿µ³²ÀÇ´ë)
±³À°½Ã°£ 05-28 206-207È£ 10:30~11:00 Çü»ç ¼Ò¼Û ºÐÀï »ç¾È¿¡ ´ëÇÑ °¨Á¤ ½Ã °í·ÁÇÒ »çÇ× ±è¼Çü(¹ý¹«¹ýÀÎ(À¯ÇÑ) ´ë·ú¾ÆÁÖ)
±³À°½Ã°£ 05-28 206-207È£ 11:00~11:20 ÁßȯÀÚ ¿Ü»ó ¿Ü°ú ¿µ¿ªÀÇ ÀÇ·á ºÐÀï°ú ¿¹¹æ ±è³²·Ä(±¹±º¿Ü»ó¼¾ÅÍ)
±³À°½Ã°£ 05-28 206-207È£ 11:20~11:35 ÀÇ·á °¨Á¤ »ç¾ÈºÐ¼® : À§Àå°ü ¿Ü°ú À¯Ç×Á¾(¿øÀڷº´¿ø)
Åä·Ð 05-28 206-207È£ 11:35~12:00 ÅäÀÇ ()
±³À°½Ã°£ 05-28 214È£ 10:30~12:00 Àü°øÀÇ ±¸¿¬ 4 TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 12:40~13:00 Virtual Reality (VR) À» ÀÌ¿ëÇÑ ¼ö·Ã ±³À°ÀÇ °¡´É¼º ¹Î¼±¿µ(°æÈñÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 13:00~13:20 Virtual Reality (VR) À» ÀÌ¿ëÇÑ ±³À°ÀÇ ½ÇÁ¦ - ÇغÎÇÐ ½Ç½ÀÀÇ ¿¹ TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 13:20~13:40 Virtual Reality (VR) À» ÀÌ¿ëÇÑ ¼ö¼ú ½Ã¿¬ÀÇ ¿¹ TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 13:40~14:10 Metaverse¸¦ ÀÌ·ç´Â ±â¼úÀÇ ÇöÀç (°³¿ä) ȫö¿î(°¡»óÇö½ÇÄÜÅÙÃ÷ »ê¾÷Çùȸ)
Åä·Ð 05-28 ´Ù¸ñÀû 2Ȧ 14:10~14:30 ÆгΠÅäÀÇ ()
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 13:00~13:15 Çѱ¹ÀÇ ÀÇ·áÇàÀ§ ºÐ·ùü°èÀÇ ÇöȲ°ú ¹®Á¦Á¡ ±èÅÂÇü(´ëÇÑ¿Ü°úÇÐȸ º¸ÇèÀ§¿øȸ °£»ç)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 13:15~13:30 Current Procedural Terminology (CPT) ÀÇ °³¿ä (¿ª»ç ¹× ÇöȲ) ±èÀÍ¿ë(´ëÇÑ¿Ü°úÇÐȸ º¸ÇèÀ§¿øȸ ºÎÀ§¿øÀå)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 13:30~13:45 Current Procedural Terminology (CPT) ÀÇ ¿î¿µ ½ÇÁ¦ : Specific Coding Issues ÀÓÁøÈ«(Çѱ¹°£´ãÃé¿Ü°úÇÐȸ º¸ÇèÀÌ»ç)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 13:45~14:00 ÀÇ·áÇàÀ§ ºÐ·ùü°è °³¼±¹æÇâ : Çѱ¹Çü Current Procedural Terminology (CPT) µµÀÔ Çʿ伺 ±è¼®ÀÏ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 14:00~14:15 ÀÇ·áÇàÀ§ ºÐ·ùü°è °³¼±¹æÇâ : °Ç°º¸Çè½É»çÆò°¡¿ø °èȹ ±èÇöÁÖ(°Ç°º¸Çè½É»çÆò°¡¿ø Á¤Ã¥¿¬±¸½Ç ºÐ·ùü°è°³¹ßºÎ)
Åä·Ð 05-28 ´Ù¸ñÀû 1Ȧ 14:15~14:30 ÆгΠÅäÀÇ ()
±³À°½Ã°£ 05-28 201-203È£ 13:00~13:25 ¼ö¼ú ÈÄ ÅëÁõ Á¶ÀýÀÇ ÃÖ½ÅÁö°ß ¹× ¼ö¼ú ÈÄ ÁøÅëÁ¦ÀÇ ºÎÀûÀýÇÑ »ç¿ë»ç·Ê ¹× ºÎÀÛ¿ë ´ëó¹ý ÀÌÈ£Áø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 13:25~13:50 ¼ö¼ú ÈÄ ¼¶¸Á°ü¸® ÀÌÀºÁÖ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-28 201-203È£ 13:50~14:15 ±Þ¼ºÅëÁõ°ü¸® °£È£»ç ÁÖµµÀÇ ¼ö¼ú ÈÄ ÅëÁõ°ü¸® ÇöȲ °¹Ì¶ó(¼¿ï¾Æ»êº´¿ø)
Åä·Ð 05-28 201-203È£ 14:15~14:30 ÅäÀÇ ()
±³À°½Ã°£ 05-28 206-207È£ 13:00~14:30 Àü°øÀÇ ±¸¿¬ 5 TBD(TBD)
±³À°½Ã°£ 05-28 214È£ 13:00~14:30 Àü°øÀÇ ±¸¿¬ 6 TBD(TBD)
±³À°½Ã°£ 05-28 301-303È£ 13:00~13:25 ´ëÀåÇ×¹® I Inflammatory Bowel Disease (IBD) ÀÇ Surgical Treatment À¯½Â¹ü(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 13:25~13:50 ´ëÀåÇ×¹® II Colorectal Cancer Surveillance and Survivorship ÇãÇõ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 13:50~14:15 ¼Ò¾Æ I ÈçÇÑ ¼Ò¾Æ¿Ü°ú ÁúȯÀÇ Áø´Ü°ú Ä¡·á: ÃֽŠµ¿ÇâÀ» Áß½ÉÀ¸·Î ¹®¼®¹è(°¿øÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 14:15~14:40 ¼Ò¾Æ II Long-term Outcomes in Pediatric Surgery ¹ÚÅÂÁø(°æ»óÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 15:00~15:15 3³âÁ¦ ¼ö·Ã°úÁ¤¿¡ ´ëÇÑ Çö½ÇÀû °íÂû - 3³âÀ» ¸¶Ä£ ÀüÀÓÀÇ ÀÔÀå I TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 15:15~15:30 3³âÁ¦ ¼ö·Ã °úÁ¤¿¡ ´ëÇÑ Çö½ÇÀû °íÂû - ÇöÁ÷ Àü°øÀÇ ÀÔÀå II TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 15:30~15:50 3³âÁ¦ ¼ö·Ã°úÁ¤¿¡ ´ëÇÑ Çö½ÇÀû °íÂû - ÁöµµÀü¹®ÀÇ ÀÔÀå I TBD(TBD)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 2Ȧ 15:50~16:10 3³âÁ¦ ¼ö·Ã°úÁ¤¿¡ ´ëÇÑ Çö½ÇÀû °íÂû - ÁöµµÀü¹®ÀÇ ÀÔÀå II TBD(TBD)
Åä·Ð 05-28 ´Ù¸ñÀû 2Ȧ 16:10~16:30 ÆгΠÅäÀÇ ()
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 15:00~15:15 ±Þ¼ºº¹ÁõȯÀÚÀÇ ¿Ü°ú ÀÀ±ÞÁø·áü°è±¸Ãà È«¼®°æ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 15:15~15:30 ¼±Áø±¹ ¿Ü°ú°è ÀÀ±ÞÀÇ·áÁ¦µµ °íÂû ¹× ¼º°úºÐ¼® Á¤À±ÅÂ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-28 ´Ù¸ñÀû 1Ȧ 15:30~15:45 ¿Ü°úÀÀ±ÞÀÇ·áü°è ¸ðµ¨ ±¸ÃàÀ» À§ÇÑ Àü¹®°¡ µ¨ÆÄÀÌÁ¶»ç ¹èÁ¤¹Î(¿µ³²ÀÇ´ë)
Åä·Ð 05-28 ´Ù¸ñÀû 1Ȧ 15:45~16:30 ÆгΠÅäÀÇ ¿°¼®¶õ / Á¤¼ºÈÆ / ¹é³²Çö(ºÎ»êÀÇ´ë / º¸°Çº¹ÁöºÎ / ¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 15:05~15:25 ¿Ü°ú Àü°øÀÇ ¼ú±â Æò°¡ ¹æ¹ý ÀÓ¸¸¼·(ÇѸ²ÀÇ´ë)
Åä·Ð 05-28 201-203È£ 15:25~15:35 ÆгΠÅäÀÇ ¼Û±³¿µ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 15:35~15:45 2022 Àü°øÀÇ ¼ú±â±³À° ÁÖ¿ä °³Æí ³»¿ë ¼Ò°³ ±è¼º±Ù(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 15:45~16:00 United Stated (US) -Guided Vascular Access ±èÇâ°æ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-28 201-203È£ 16:00~16:15 Cadaver¸¦ ÀÌ¿ëÇÑ ¿Ü°ú¼ú±â ±³À° ±èÇüÁø(°¡Å縯ÀÇ´ë)
Åä·Ð 05-28 201-203È£ 16:15~16:30 ¼ú±â ±³À° °³Æí¾È ÅäÀÇ ÀÌÇõÁØ / ±èÀçÈÆ(¼¿ïÀÇ´ë / ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05-28 206-207È£ 15:00~15:20 ÀÔ¿øÀü´ãÀü¹®ÀÇÁ¦µµ º»»ç¾÷ 1³â-ÇâÈÄ °úÁ¦ Á¤À±ºó(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-28 206-207È£ 15:20~15:40 Veiled & Revealed Impact of Surgical Hospitalist System ¹Ú¹Î¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-28 206-207È£ 15:40~16:00 Surgical Oncologist : Role of Surgical Hospitalist ±èÁöȯ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-28 206-207È£ 16:00~16:20 Adjacent Educator for Resident Training : Role of Surgical Hospitalist Á¤ÀºÁÖ(¿¬¼¼ÀÇ´ë)
Åä·Ð 05-28 206-207È£ 16:20~16:30 ÅäÀÇ ()
±³À°½Ã°£ 05-28 214È£ 15:00~16:30 Àü°øÀÇ ±¸¿¬7 TBD(TBD)
±³À°½Ã°£ 05-28 301-303È£ 15:00~15:25 °£´ãÃé I Surgical Indication of Pancreas Intraductal Papillary Mucinous Neoplasm (IPMN) ÀÌÀçÈÆ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 15:25~15:50 °£´ãÃé II °£ÀÌ½Ä ÃÖ½ÅÁö°ß ÃÖ¿µ·Ï(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 15:50~16:15 À¯¹æ I À¯¹æ¾Ï Àü±¸º´º¯°ú »óÇdz»¾ÏÀÇ ÀÌÇØ ¹× Ä¡·á¿øÄ¢ ¹Ú¹ÎÈ£(Àü³²ÀÇ´ë)
±³À°½Ã°£ 05-28 301-303È£ 16:15~16:40 À¯¹æ II À¯¹æ¾Ï ¸²ÇÁÀý ¼ö¼úÀÇ ÃֽŠÁö°ß ÀÌÁö¿¬(°æºÏÀÇ´ë)